A preliminary study of paraoxonase-1 in infected patients with an indwelling central venous catheter

Clinical Biochemistry

Volumn 49, Issue 6, 2016, Pages 449-457

  Iftimie, Simona ^a   García Heredia, Anabel ^a   Pujol, Isabel ^a   Ballester, Frederic ^a   Fort Gallifa, Isabel ^a   Simó, Josep M ^a   Joven, Jorge ^a   Castro, Antoni ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Biomarkers; Catheters; Infection; Paraoxonase 1

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; GLUCONOLACTONASE; IMMUNOSUPPRESSIVE AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYPEPTIDE ANTIBIOTIC AGENT; PROCALCITONIN; QUINOLONE DERIVATIVE; PON1 PROTEIN, HUMAN;

ABDOMINAL ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; CHEMICAL PARAMETERS; CONCURRENT INFECTION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SERUM; ADVERSE EFFECTS; ENZYMOLOGY; INFECTION; METABOLISM; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CENTRAL VENOUS CATHETERS; FEMALE; HUMANS; INFECTION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84947300026     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.11.006     Document Type: Article

References (40)

1. O'Grady N.P., Alexander M., Burns L.A., Dellinger E.P., Garland J., Heard S.O., et al. Healthcare infection control practices advisory committee (HICPAC): guidelines for the prevention of intravascular catheter-related infections. Clin. Infect. Dis. 2011, 52:e162-e163.
2. Theodorou V.P., Papaioannou V.E., Tripsianis G.A., Panopoulou M.K., Christophoridis E.K., Kouliatsis G.A., et al. Procalcitonin and procalcitonin kinetics for diagnosis and prognosis of intravascular catheter-related bloodstream infections in selected critically ill patients: a prospective observational study. BMC Infect. Dis. 2012, 12:247.
3. Henriquez-Camacho C., Losa J. Biomarkers for sepsis. Biomed. Res. Int. 2014, 2014:547818.
4. Camps J., Marsillach J., Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 2009, 46:83-106.
5. Schweikert E.M., Amort J., Wilgenbus P., Förstermann U., Teiber J.F., Horke S. Paraoxonases-2 and -3 are important defense enzymes against Pseudomonas aeruginosa virulence factors due to their anti-oxidative and anti-inflammatory properties. J. Lipids 2012, 2012:352857.
6. Stoltz D.A., Ozer E.A., Ng C.J., Yu J.M., Reddy S.T., Lusis A.J., et al. Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292:L852-L860.
7. Devarajan A., Bourquard N., Grijalva V.R., Gao F., Ganapathy E., Verma J., et al. Role of PON2 in innate immune response in an acute infection model. Mol. Genet. Metab. 2013, 110:362-370.
8. Mete R., Oran M., Alpsoy S., Gunes H., Tulubas F., Turan C., et al. Carotid intima-media thickness and serum paraoxonase-1 activity in patients with Helicobacter pylori. Eur. Rev. Med. Pharmacol. Sci. 2013, 17:2884-2889.
9. Campbell L.A., Yaraei K., Van Lenten B., Chait A., Blessing E., Kuo C.C., et al. The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis. Microbes Infect. 2010, 12:598-606.
10. Karsen H., Binici I., Sunnetcioglu M., Baran A.I., Ceylan M.R., Selek S., et al. Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B. Afr. Health Sci. 2012, 12:114-118.
11. Parra S., Marsillach J., Aragonés G., Beltrán R., Montero M., Coll B., et al. Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J. Infect. Dis. 2010, 201:627-634.
12. Richter R.J., Jarvik G.P., Furlong C.E. Paraoxonase 1 status as a risk factor for disease or exposure. Adv. Exp. Med. Biol. 2010, 660:29-35.
13. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Healthcare infection control practices advisory committee: guidelines for the prevention of intravascular catheter-related infections. Infect. Control Hosp. Epidemiol. 2002, 23:759-769.
14. McCabe W.R., Jackson G.G. Gram-negative bacteremia. I. Etiology and ecology. Arch. Intern. Med. 1962, 110:847-864.
15. Berkman L.F., Leo-Summers L., Horwitz R.I. Emotional support and survival after myocardial infarction. A prospective, population-based study of the elderly. Ann. Intern. Med. 1992, 117:1003-1009.
16. Ferré N., Camps J., Fernández-Ballart J., Arija V., Murphy M.M., Ceruelo S., et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 2003, 49:1491-1497.
17. Marsillach J., Aragonès G., Beltrán R., Caballeria J., Pedro-Botet J., Morcillo-Suárez C., et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin. Biochem. 2009, 42:91-98.
18. Martinelli N., Garcia-Heredia A., Roca H., Aranda N., Arija V., Mackness B., et al. Paraoxonase-1 status in patients with hereditary hemochromatosis. J. Lipid Res. 2013, 54:1484-1492.
19. Maki D.G., Weise C.E., Sarafin H.W. A semiquantitative culture method for identifying intravenous-catheter-related infection. N. Engl. J. Med. 1977, 296:1305-1309.
20. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for disease control and prevention. MMWR Recomm. Rep. 2002, 51:1-29.
21. O'Grady N.P., Alexander M., Burns L.A., Dellinger E.P., Garland J., Heard S.O., et al. Healthcare infection control practices advisory committee (HICPAC). guidelines for the prevention of intravascular catheter-related infections. Clin. Infect. Dis. 2011, 52:e162-e193.
22. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39:561-577.
23. Khersonsky O., Roodveldt C., Tawfik D.S. Enzyme promiscuity: evolutionary and mechanistic aspects. Curr. Opin. Chem. Biol. 2006, 10:498-508.
24. Camps J., Pujol I., Ballester F., Joven J., Simó J.M. Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in Gram-negative bacteria. Antimicrob. Agents Chemother. 2011, 55:1325-1331.
25. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 1999, 26:892-904.
26. Ekinci D., Beydemir S. Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases. Eur. J. Pharmacol. 2009, 617:84-89.
27. Işgör M.M., Beydemir S. Some cardiovascular therapeutics inhibit paraoxonase 1 (PON1) from human serum. Eur. J. Pharmacol. 2010, 645:135-142.
28. Abelló D., Sancho E., Camps J., Joven J. Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: a systematic review. Int. J. Mol. Sci. 2014, 15:20997-21010.
29. Daniels J.M., Schoorl M., Snijders D., Knol D.L., Lutter R., Jansen H.M., et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010, 138:1108-1115.
30. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis. 2004, 9:206-217.
31. Simon L., Saint-Louis P., Amre D.K., Lacroix J., Gauvin F. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr. Crit. Care Med. 2008, 9:407-413.
32. Schuetz P., Christ-Crain M., Müller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr. Opin. Crit. Care 2007, 13:578-585.
33. Tromp M., Lansdorp B., Bleeker-Rovers C.P., Gunnewiek J.M., Kullberg B.J., Pickkers P. Serial and panel analyses of biomarkers do not improve the prediction of bacteriemia compared to one procalcitonin measurement. J. Infect. 2012, 65:292-301.
34. Garnacho-Montero J., Huici-Moreno M.J., Gutiérrez-Pizarraya A., López I., Márquez-Vácaro J.A., Macher H., et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Crit. Care 2014, 18:R116.
35. Magrini L., Gagliano G., Travaglino F., Vetrone F., Marino R., Cardelli P., et al. Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department. Clin. Chem. Lab. Med. 2014, 52:1465-1472.
36. Andrijevic I., Matijasevic J., Andrijevic L., Kovacevic T., Zaric B. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. Ann. Thorac. Med. 2014, 9:162-167.
37. Dupuy A.M., Philippart F., Péan Y., Lasocki S., Charles P.E., Chalumeau M., et al. Maurice rapin institute biomarkers group: role of biomarkers in the management of antibiotic therapy: an expert panel review : I-currently available biomarkers for clinical use in acute infections. Ann. Intensive Care 2013, 3:22.
38. Su L., Han B., Liu C., Liang L., Jiang Z., Deng J., et al. Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect. Dis. 2012, 12:157.
39. Holm A., Pedersen S.S., Nexoe J., Obel N., Nielsen L.P., Koldkjaer O., et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br. J. Gen. Pract. 2007, 57:555-560.
40. Suchocka Z., Swatowska J., Pachecka J., Suchocki P. RP-HPLC determination of paraoxonase 3 activity in human blood serum. J. Pharm. Biomed. Anal. 2006, 42:113-119.